logo

Kiniksa Pharmaceuticals, Ltd. (KNSA)



Trade KNSA now with
  Date
  Headline
7/16/2020 7:40:20 AM Kiniksa: FDA Grants U.S. Orphan Drug Designation For Rilonacept For The Treatment Of Pericarditis
6/29/2020 7:23:16 AM Kiniksa Announces Positive Data From RHAPSODY, A Phase 3 Trial Of Rilonacept In Recurrent Pericarditis
6/8/2020 8:10:17 AM Kiniksa Reports 28-Day Clinical Outcomes Data From Mavrilimumab Treatment Protocol
5/14/2020 12:17:06 AM Kiniksa Pharma Prices Public Offering Of 2.4 Mln Class A Common Shares At $18.25/Shr
5/11/2020 7:45:07 AM Kiniksa Reports Data For Mavrilimumab And For Vixarelimab
12/11/2019 8:33:58 AM Kite And Kiniksa Enter Clinical Collaboration To Conduct Phase 2, Multicenter Study Of Mavrilimumab
8/12/2019 4:07:33 PM Kiniksa Q2 Loss/share $0.68 Vs. Loss $1.11 Year Ago
8/5/2019 7:35:42 AM Kiniksa Announces Collaboration With The Myocarditis Foundation
3/19/2019 7:33:29 AM Wedbush Reiterates Kiniksa Pharmaceuticals, Ltd. (KNSA) At Outperform With $30 Price Target
1/31/2019 8:58:23 AM Kiniksa Prices Public Offering Of 2.65 Mln Class A Common Shares At $18.26 Per Share
1/3/2019 7:35:57 AM Kiniksa Reports Active U.S. Investigational New Drug Application For Mavrilimumab
12/12/2018 6:51:51 AM Wedbush Reiterates Kiniksa Pharmaceuticals, Ltd. (KNSA) At Outperform With $33 Up From $31 Price Target
12/11/2018 7:32:53 AM Kiniksa Announces Rilonacept Interim Phase 2 Clinical Data And Initiates Pivotal Phase 3 Clinical Trial